Investigating a new treatment for migraine using adenosine A3 receptor agonists
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine
This study is looking into how a new type of medication might help people with migraines by reducing pain and inflammation, especially since many current treatments don’t work well or aren’t safe for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10992110 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular mechanisms of migraine and exploring the potential of adenosine A3 receptor (A3AR) agonists as a new treatment option. Many current migraine therapies are ineffective or unsafe for certain patients, highlighting the need for novel approaches. The study will investigate how A3AR agonists can reduce pain and inflammation associated with migraines by targeting specific pathways in the body. By using various models, researchers aim to provide insights that could lead to effective treatments for those suffering from migraines.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who experience chronic migraines and have not found relief with existing therapies.
Not a fit: Patients who do not suffer from migraines or have contraindications to adenosine A3 receptor agonists may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for migraine sufferers who currently have limited options.
How similar studies have performed: While the use of adenosine A3 receptor agonists is a relatively novel approach, preliminary data suggest promising results in related pain models, indicating potential for success.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Akerman, Simon — University of Maryland Baltimore
- Study coordinator: Akerman, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.